 Kevin Messacar
Concepts (246)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Enterovirus Infections | 32 | 2025 | 171 | 11.390 |
Why?
| | Enterovirus D, Human | 20 | 2025 | 82 | 6.990 |
Why?
| | Myelitis | 24 | 2025 | 98 | 6.870 |
Why?
| | Central Nervous System Viral Diseases | 16 | 2025 | 73 | 5.490 |
Why?
| | Neuromuscular Diseases | 16 | 2025 | 105 | 5.350 |
Why?
| | Enterovirus | 14 | 2025 | 78 | 4.910 |
Why?
| | Meningitis | 8 | 2022 | 80 | 3.930 |
Why?
| | Encephalitis | 12 | 2022 | 132 | 3.900 |
Why?
| | Respiratory Tract Infections | 11 | 2025 | 372 | 3.500 |
Why?
| | Disease Outbreaks | 18 | 2025 | 339 | 3.440 |
Why?
| | Parechovirus | 4 | 2025 | 8 | 2.230 |
Why?
| | Anti-Infective Agents | 5 | 2023 | 243 | 2.190 |
Why?
| | Picornaviridae Infections | 4 | 2025 | 45 | 2.070 |
Why?
| | Multiplex Polymerase Chain Reaction | 4 | 2020 | 51 | 1.870 |
Why?
| | Nervous System Diseases | 5 | 2020 | 251 | 1.800 |
Why?
| | Paralysis | 5 | 2020 | 69 | 1.670 |
Why?
| | Hospitals, Pediatric | 5 | 2020 | 505 | 1.560 |
Why?
| | Molecular Diagnostic Techniques | 6 | 2020 | 97 | 1.440 |
Why?
| | Cerebrospinal Fluid | 6 | 2019 | 89 | 1.430 |
Why?
| | Central Nervous System Infections | 2 | 2022 | 35 | 1.400 |
Why?
| | Enterovirus A, Human | 2 | 2022 | 12 | 1.380 |
Why?
| | Child | 49 | 2025 | 20636 | 1.310 |
Why?
| | Antimicrobial Stewardship | 4 | 2023 | 98 | 1.300 |
Why?
| | Communicable Diseases | 4 | 2021 | 145 | 1.220 |
Why?
| | Colorado | 21 | 2025 | 4369 | 1.220 |
Why?
| | Epidemiological Monitoring | 3 | 2021 | 49 | 1.190 |
Why?
| | Herpesvirus 6, Human | 2 | 2019 | 13 | 1.110 |
Why?
| | Anti-Bacterial Agents | 6 | 2024 | 1689 | 1.060 |
Why?
| | Viruses | 4 | 2023 | 99 | 1.050 |
Why?
| | Child, Preschool | 31 | 2025 | 10378 | 1.000 |
Why?
| | Humans | 80 | 2025 | 128020 | 0.880 |
Why?
| | Respiratory Tract Diseases | 1 | 2024 | 148 | 0.790 |
Why?
| | Infant | 24 | 2025 | 8912 | 0.790 |
Why?
| | Influenza, Human | 3 | 2020 | 600 | 0.780 |
Why?
| | Simplexvirus | 2 | 2020 | 80 | 0.780 |
Why?
| | Nervous System Malformations | 1 | 2022 | 37 | 0.750 |
Why?
| | Brain Diseases | 2 | 2020 | 136 | 0.740 |
Why?
| | Sepsis | 2 | 2018 | 562 | 0.730 |
Why?
| | Cranial Nerve Diseases | 3 | 2017 | 41 | 0.720 |
Why?
| | Influenza A Virus, H3N2 Subtype | 1 | 2020 | 43 | 0.660 |
Why?
| | Virus Diseases | 1 | 2022 | 209 | 0.660 |
Why?
| | Acyclovir | 1 | 2020 | 99 | 0.660 |
Why?
| | Muscle Hypotonia | 2 | 2020 | 32 | 0.650 |
Why?
| | Exanthema Subitum | 1 | 2019 | 3 | 0.650 |
Why?
| | Drug Utilization | 2 | 2017 | 166 | 0.640 |
Why?
| | Hospitals, Teaching | 1 | 2019 | 112 | 0.630 |
Why?
| | Hepatitis | 1 | 2019 | 47 | 0.630 |
Why?
| | Encephalitis, Viral | 2 | 2020 | 42 | 0.620 |
Why?
| | Taenia solium | 1 | 2018 | 5 | 0.620 |
Why?
| | Neurocysticercosis | 1 | 2018 | 8 | 0.620 |
Why?
| | Abdomen | 1 | 2019 | 116 | 0.610 |
Why?
| | Meningoencephalitis | 2 | 2019 | 25 | 0.610 |
Why?
| | Gastroenteritis | 1 | 2019 | 66 | 0.600 |
Why?
| | Polymerase Chain Reaction | 6 | 2024 | 1020 | 0.600 |
Why?
| | Fluoxetine | 1 | 2018 | 52 | 0.590 |
Why?
| | Bacteriological Techniques | 1 | 2018 | 68 | 0.590 |
Why?
| | Retrospective Studies | 18 | 2024 | 14404 | 0.570 |
Why?
| | Diagnosis, Differential | 6 | 2019 | 1408 | 0.560 |
Why?
| | Metagenomics | 6 | 2023 | 154 | 0.560 |
Why?
| | Hospitalization | 7 | 2020 | 2057 | 0.540 |
Why?
| | Vaccines | 1 | 2022 | 394 | 0.540 |
Why?
| | Seizures | 1 | 2020 | 400 | 0.530 |
Why?
| | Antiviral Agents | 2 | 2020 | 710 | 0.520 |
Why?
| | Analgesia, Obstetrical | 1 | 2016 | 18 | 0.520 |
Why?
| | Bacterial Infections | 1 | 2018 | 232 | 0.520 |
Why?
| | Analgesia, Epidural | 1 | 2016 | 23 | 0.520 |
Why?
| | Male | 34 | 2025 | 62758 | 0.510 |
Why?
| | Fever | 2 | 2019 | 295 | 0.500 |
Why?
| | Bacteria | 3 | 2023 | 812 | 0.490 |
Why?
| | Microbial Sensitivity Tests | 1 | 2016 | 348 | 0.490 |
Why?
| | Health Resources | 1 | 2016 | 112 | 0.470 |
Why?
| | Parotitis | 1 | 2014 | 6 | 0.450 |
Why?
| | Motor Neurons | 1 | 2016 | 238 | 0.440 |
Why?
| | Herpesviridae Infections | 1 | 2015 | 134 | 0.430 |
Why?
| | Acute Kidney Injury | 1 | 2021 | 777 | 0.430 |
Why?
| | Female | 31 | 2025 | 68017 | 0.410 |
Why?
| | Magnetic Resonance Imaging | 5 | 2020 | 3371 | 0.400 |
Why?
| | United States | 15 | 2024 | 13785 | 0.400 |
Why?
| | Pregnancy Complications, Infectious | 1 | 2016 | 363 | 0.390 |
Why?
| | Infant, Newborn | 9 | 2019 | 5688 | 0.380 |
Why?
| | Referral and Consultation | 1 | 2017 | 724 | 0.380 |
Why?
| | Pediatrics | 1 | 2019 | 1044 | 0.370 |
Why?
| | High-Throughput Nucleotide Sequencing | 5 | 2023 | 484 | 0.370 |
Why?
| | Quality Improvement | 1 | 2019 | 1093 | 0.370 |
Why?
| | Prospective Studies | 5 | 2025 | 7035 | 0.340 |
Why?
| | Seasons | 3 | 2019 | 498 | 0.340 |
Why?
| | Cohort Studies | 6 | 2024 | 5378 | 0.340 |
Why?
| | Brain | 3 | 2018 | 2615 | 0.340 |
Why?
| | Meningitis, Aseptic | 2 | 2020 | 13 | 0.340 |
Why?
| | Internship and Residency | 1 | 2019 | 1043 | 0.330 |
Why?
| | Attitude of Health Personnel | 1 | 2017 | 1088 | 0.330 |
Why?
| | Genome, Microbial | 2 | 2019 | 7 | 0.290 |
Why?
| | Adolescent | 17 | 2025 | 20158 | 0.280 |
Why?
| | Rhinovirus | 2 | 2017 | 56 | 0.230 |
Why?
| | Paraplegia | 2 | 2015 | 56 | 0.230 |
Why?
| | Sequence Analysis, DNA | 5 | 2023 | 771 | 0.230 |
Why?
| | Pleural Effusion | 1 | 2024 | 49 | 0.230 |
Why?
| | Mycoplasma pneumoniae | 1 | 2024 | 54 | 0.230 |
Why?
| | Pneumonia, Mycoplasma | 1 | 2024 | 55 | 0.230 |
Why?
| | Acute Disease | 4 | 2019 | 961 | 0.210 |
Why?
| | Time Factors | 4 | 2018 | 6479 | 0.210 |
Why?
| | Streptococcus pneumoniae | 1 | 2024 | 158 | 0.210 |
Why?
| | Adenoviridae Infections | 1 | 2023 | 15 | 0.200 |
Why?
| | Community-Acquired Infections | 1 | 2024 | 153 | 0.200 |
Why?
| | Arbovirus Infections | 2 | 2020 | 19 | 0.200 |
Why?
| | Respiratory Syncytial Virus, Human | 1 | 2023 | 68 | 0.200 |
Why?
| | Liver Failure, Acute | 1 | 2023 | 63 | 0.200 |
Why?
| | Respiratory System | 1 | 2023 | 152 | 0.200 |
Why?
| | Fungi | 1 | 2023 | 136 | 0.190 |
Why?
| | Uncertainty | 1 | 2022 | 114 | 0.190 |
Why?
| | Respiratory Syncytial Virus Infections | 1 | 2023 | 119 | 0.190 |
Why?
| | Medical Oncology | 1 | 2023 | 271 | 0.180 |
Why?
| | Lung | 1 | 2014 | 3745 | 0.180 |
Why?
| | Hashimoto Disease | 1 | 2021 | 11 | 0.180 |
Why?
| | Brain Abscess | 1 | 2020 | 10 | 0.170 |
Why?
| | Esophageal Perforation | 1 | 2020 | 15 | 0.170 |
Why?
| | Esophageal Fistula | 1 | 2020 | 18 | 0.170 |
Why?
| | Antigens, Viral | 2 | 2019 | 174 | 0.170 |
Why?
| | Meningitis, Viral | 1 | 2020 | 21 | 0.170 |
Why?
| | Encephalitis, Herpes Simplex | 1 | 2020 | 21 | 0.170 |
Why?
| | Muscle Weakness | 1 | 2020 | 83 | 0.170 |
Why?
| | Confusion | 1 | 2020 | 26 | 0.170 |
Why?
| | Pandemics | 3 | 2023 | 1473 | 0.170 |
Why?
| | Immunocompetence | 1 | 2019 | 43 | 0.160 |
Why?
| | Genetic Diseases, X-Linked | 1 | 2019 | 23 | 0.160 |
Why?
| | Myelitis, Transverse | 1 | 2019 | 3 | 0.160 |
Why?
| | HIV Infections | 1 | 2014 | 2703 | 0.160 |
Why?
| | Seroepidemiologic Studies | 1 | 2019 | 155 | 0.160 |
Why?
| | Agammaglobulinemia | 1 | 2019 | 33 | 0.160 |
Why?
| | Foreign Bodies | 1 | 2020 | 101 | 0.160 |
Why?
| | Antibodies, Helminth | 1 | 2018 | 6 | 0.160 |
Why?
| | Myelin-Oligodendrocyte Glycoprotein | 1 | 2019 | 49 | 0.160 |
Why?
| | Meningitis, Bacterial | 1 | 2019 | 47 | 0.150 |
Why?
| | Canada | 2 | 2019 | 344 | 0.150 |
Why?
| | Body Fluids | 1 | 2018 | 62 | 0.150 |
Why?
| | Leukocyte Count | 1 | 2018 | 325 | 0.140 |
Why?
| | Arboviruses | 1 | 2017 | 13 | 0.140 |
Why?
| | Controlled Before-After Studies | 1 | 2017 | 14 | 0.140 |
Why?
| | Headache | 1 | 2018 | 137 | 0.140 |
Why?
| | Program Development | 1 | 2019 | 357 | 0.140 |
Why?
| | Neuromyelitis Optica | 1 | 2019 | 128 | 0.140 |
Why?
| | Refusal to Treat | 1 | 2017 | 17 | 0.140 |
Why?
| | Diagnostic Tests, Routine | 1 | 2018 | 101 | 0.140 |
Why?
| | RNA | 1 | 2023 | 881 | 0.140 |
Why?
| | Drug Utilization Review | 1 | 2017 | 57 | 0.140 |
Why?
| | Treatment Failure | 1 | 2018 | 338 | 0.140 |
Why?
| | Prevalence | 2 | 2015 | 2541 | 0.140 |
Why?
| | Sensitivity and Specificity | 2 | 2019 | 1813 | 0.140 |
Why?
| | Herpes Simplex | 1 | 2017 | 93 | 0.140 |
Why?
| | Movement Disorders | 1 | 2017 | 52 | 0.130 |
Why?
| | Densovirus | 1 | 2016 | 2 | 0.130 |
Why?
| | Communicable Disease Control | 1 | 2017 | 70 | 0.130 |
Why?
| | Muscular Diseases | 1 | 2017 | 107 | 0.130 |
Why?
| | Drug Resistance | 1 | 2017 | 165 | 0.130 |
Why?
| | Anti-N-Methyl-D-Aspartate Receptor Encephalitis | 1 | 2016 | 16 | 0.130 |
Why?
| | Encephalomyelitis | 1 | 2016 | 9 | 0.130 |
Why?
| | Electromyography | 2 | 2017 | 381 | 0.130 |
Why?
| | Eosinophilia | 1 | 2018 | 204 | 0.130 |
Why?
| | Neoplasms | 2 | 2023 | 2460 | 0.130 |
Why?
| | Balamuthia mandrillaris | 1 | 2015 | 4 | 0.130 |
Why?
| | Amebiasis | 1 | 2015 | 5 | 0.130 |
Why?
| | Combined Modality Therapy | 1 | 2019 | 1199 | 0.120 |
Why?
| | Genome, Mitochondrial | 1 | 2015 | 26 | 0.120 |
Why?
| | Early Diagnosis | 1 | 2016 | 234 | 0.120 |
Why?
| | Treatment Outcome | 3 | 2019 | 10110 | 0.120 |
Why?
| | Liver Transplantation | 1 | 2023 | 799 | 0.120 |
Why?
| | North America | 1 | 2016 | 289 | 0.120 |
Why?
| | Program Evaluation | 1 | 2019 | 872 | 0.120 |
Why?
| | Influenza A Virus, H1N1 Subtype | 1 | 2016 | 146 | 0.120 |
Why?
| | Case-Control Studies | 2 | 2020 | 3324 | 0.120 |
Why?
| | La Crosse virus | 1 | 2014 | 6 | 0.120 |
Why?
| | Biopsy | 1 | 2018 | 1077 | 0.120 |
Why?
| | Encephalitis, California | 1 | 2014 | 11 | 0.110 |
Why?
| | Hospitals | 1 | 2019 | 631 | 0.110 |
Why?
| | Kidney | 1 | 2021 | 1306 | 0.110 |
Why?
| | West Nile Fever | 1 | 2014 | 49 | 0.110 |
Why?
| | Adult | 6 | 2023 | 35177 | 0.110 |
Why?
| | Neoplasm Recurrence, Local | 1 | 2019 | 955 | 0.100 |
Why?
| | Radiography, Thoracic | 1 | 2014 | 163 | 0.100 |
Why?
| | Clinical Competence | 1 | 2019 | 1007 | 0.100 |
Why?
| | Orthomyxoviridae | 1 | 2012 | 40 | 0.100 |
Why?
| | Neuroimaging | 1 | 2014 | 278 | 0.100 |
Why?
| | Critical Care | 1 | 2017 | 550 | 0.100 |
Why?
| | Temperature | 1 | 2015 | 628 | 0.100 |
Why?
| | Anti-Retroviral Agents | 1 | 2014 | 230 | 0.100 |
Why?
| | Population Surveillance | 1 | 2014 | 426 | 0.090 |
Why?
| | Risk Assessment | 1 | 2019 | 3223 | 0.080 |
Why?
| | Risk Factors | 2 | 2020 | 9696 | 0.080 |
Why?
| | Follow-Up Studies | 2 | 2017 | 4853 | 0.080 |
Why?
| | Animals | 3 | 2019 | 34487 | 0.080 |
Why?
| | Young Adult | 4 | 2019 | 12282 | 0.070 |
Why?
| | Muscle, Skeletal | 1 | 2017 | 1620 | 0.070 |
Why?
| | Quality of Life | 1 | 2018 | 2672 | 0.060 |
Why?
| | California | 2 | 2019 | 398 | 0.060 |
Why?
| | Immunoglobulin G | 2 | 2019 | 842 | 0.060 |
Why?
| | Pneumonia, Pneumococcal | 1 | 2024 | 41 | 0.060 |
Why?
| | Tomography, X-Ray Computed | 1 | 2014 | 2509 | 0.060 |
Why?
| | Cluster Analysis | 2 | 2016 | 477 | 0.060 |
Why?
| | Pregnancy | 1 | 2016 | 6355 | 0.050 |
Why?
| | Computational Biology | 2 | 2019 | 595 | 0.050 |
Why?
| | Adenoviridae | 1 | 2023 | 189 | 0.050 |
Why?
| | Phylogeny | 2 | 2016 | 838 | 0.050 |
Why?
| | Immunologic Surveillance | 1 | 2022 | 26 | 0.050 |
Why?
| | Methicillin-Resistant Staphylococcus aureus | 1 | 2024 | 215 | 0.050 |
Why?
| | Spatio-Temporal Analysis | 1 | 2021 | 27 | 0.050 |
Why?
| | Models, Theoretical | 1 | 2024 | 541 | 0.040 |
Why?
| | Africa, Western | 1 | 2020 | 17 | 0.040 |
Why?
| | Technology | 1 | 2021 | 84 | 0.040 |
Why?
| | Living Donors | 1 | 2023 | 287 | 0.040 |
Why?
| | Child, Hospitalized | 1 | 2020 | 48 | 0.040 |
Why?
| | Patient Outcome Assessment | 1 | 2020 | 125 | 0.040 |
Why?
| | Consciousness Disorders | 1 | 2019 | 19 | 0.040 |
Why?
| | Encephalomyelitis, Acute Disseminated | 1 | 2019 | 11 | 0.040 |
Why?
| | Picornaviridae | 1 | 2019 | 17 | 0.040 |
Why?
| | Disease Susceptibility | 1 | 2021 | 331 | 0.040 |
Why?
| | Global Health | 1 | 2020 | 327 | 0.040 |
Why?
| | Neural Conduction | 1 | 2017 | 82 | 0.030 |
Why?
| | Sequence Analysis, RNA | 1 | 2019 | 427 | 0.030 |
Why?
| | Atrophy | 1 | 2017 | 170 | 0.030 |
Why?
| | Sequence Homology | 1 | 2016 | 40 | 0.030 |
Why?
| | Health Information Systems | 1 | 2016 | 17 | 0.030 |
Why?
| | Open Reading Frames | 1 | 2016 | 115 | 0.030 |
Why?
| | Electronic Health Records | 1 | 2023 | 973 | 0.030 |
Why?
| | Guatemala | 1 | 2017 | 311 | 0.030 |
Why?
| | Genome, Viral | 1 | 2016 | 127 | 0.030 |
Why?
| | Antibodies, Viral | 1 | 2019 | 601 | 0.030 |
Why?
| | RNA, Viral | 1 | 2019 | 615 | 0.030 |
Why?
| | Disease-Free Survival | 1 | 2017 | 647 | 0.030 |
Why?
| | Aftercare | 1 | 2017 | 206 | 0.030 |
Why?
| | Intensive Care Units, Pediatric | 1 | 2016 | 201 | 0.030 |
Why?
| | Cost of Illness | 1 | 2016 | 277 | 0.030 |
Why?
| | DNA, Viral | 1 | 2016 | 348 | 0.030 |
Why?
| | Brain Stem | 1 | 2014 | 98 | 0.030 |
Why?
| | Length of Stay | 1 | 2019 | 1114 | 0.030 |
Why?
| | Models, Biological | 1 | 2021 | 1689 | 0.030 |
Why?
| | Patient Reported Outcome Measures | 1 | 2017 | 368 | 0.030 |
Why?
| | Incidence | 1 | 2019 | 2614 | 0.020 |
Why?
| | Survival Rate | 1 | 2017 | 1870 | 0.020 |
Why?
| | Middle Aged | 3 | 2019 | 30813 | 0.020 |
Why?
| | Logistic Models | 1 | 2016 | 1975 | 0.020 |
Why?
| | Reproducibility of Results | 1 | 2019 | 3009 | 0.020 |
Why?
| | Autoantibodies | 1 | 2019 | 1461 | 0.020 |
Why?
| | Critical Illness | 1 | 2016 | 755 | 0.020 |
Why?
| | Prognosis | 1 | 2019 | 3766 | 0.020 |
Why?
| | Severity of Illness Index | 1 | 2016 | 2703 | 0.020 |
Why?
| | Aged | 2 | 2019 | 21892 | 0.020 |
Why?
|
|
Messacar's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|